Health Status of the Oldest Adult Survivors of Cancer During Childhood
Overview
Authors
Affiliations
Background: Young adult survivors of childhood cancer have an increased risk for treatment-related morbidity and mortality. In this study, the authors assessed how treatment for childhood cancer affects older-adult health and health practices.
Methods: One hundred seven adults treated for childhood cancer between 1947 and 1968, known to have survived past age 50 years, were identified from a single-institution cohort established in 1975. Updated vital status on eligible cases was obtained from public records. Survivors and a control group of their age-matched siblings and cousins completed a mailed survey to assess physical and social function, healthcare practices, and the prevalence of common adult illnesses.
Results: Of the 107 survivors known to be alive at age 50 years, 16 were deceased at follow-up; 7 deaths could be associated with prior treatment (second malignancy in radiation field [3], small bowel obstruction after abdominal radiation [2], and cardiac disease after chest irradiation [2]). The 55 survivors (median age, 56 years; range, 51-71 years), and 32 family controls (median age, 58 years; range, 48-70 years), reported similar health practices, health-related quality of life, and social function. However, survivors reported more frequent visits to healthcare providers (P < .05), more physical impairments (P < .05), fatigue (P = .02), hypertension (P = .001), and coronary artery disease (P = .01). An increased risk of hypertension was associated with nephrectomy during childhood (odds ratio, 18.9; 95% confidence interval, 3.0-118.8).
Conclusions: The oldest adult survivors of childhood cancer continue to be at risk for treatment-related complications that potentially decrease their life expectancy and compromise their quality of life.
Cancer survivorship programs at the Dana-Farber Cancer Institute.
Partridge A, Morgans A, Knelson L, Recklitis C, Nekhlyudov L, Chi S J Cancer Surviv. 2024; 18(1):34-41.
PMID: 38294603 PMC: 11003887. DOI: 10.1007/s11764-023-01525-8.
Nichols H, Wernli K, Chawla N, OMeara E, Figueroa Gray M, Green L Curr Epidemiol Rep. 2023; 10(3):115-124.
PMID: 37700859 PMC: 10495081. DOI: 10.1007/s40471-022-00286-9.
Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.
Ramachandran B, Rajkumar T, Gopisetty G Am J Transl Res. 2021; 13(11):12181-12194.
PMID: 34956445 PMC: 8661172.
van Deuren S, Penson A, van Dulmen-den Broeder E, Grootenhuis M, van der Heiden-van der Loo M, Bronkhorst E Cancer. 2021; 128(5):1110-1121.
PMID: 34724201 PMC: 9298343. DOI: 10.1002/cncr.33993.
Christen S, Roser K, Mulder R, Ilic A, Lie H, Loonen J J Cancer Surviv. 2020; 14(6):923-938.
PMID: 32839902 PMC: 7572340. DOI: 10.1007/s11764-020-00904-9.